Pioneering a New Cancer Treatment Paradigm

Treatment resistance, cancer relapse and metastasis are often the unfortunate outcome for patients suffering from cancer. At HiberCell, we are working to address these under-explored areas of cancer biology by leveraging our insights in adaptive stress and immune suppression, together with our QuAD3 machine learning (ML) and artificial intelligence (AI) platform, to build a pipeline of innovative cancer therapeutic candidates. We believe that exploring pathways critical to adaptive stress and innate and adaptive immunity has the potential to bring us closer to realizing our vision of ‘a world in which cancer doesn’t win.’

Pioneering a New Cancer Treatment Paradigm

Treatment resistance, cancer relapse and metastasis are often the unfortunate outcome for patients suffering from cancer. At HiberCell, we are working to address these under-explored areas of cancer biology by leveraging our insights in adaptive stress and immune suppression, together with our QuAD3 machine learning (ML) and artificial intelligence (AI) platform, to build a pipeline of innovative cancer therapeutic candidates. We believe that exploring pathways critical to adaptive stress and innate and adaptive immunity has the potential to bring us closer to realizing our vision of ‘a world in which cancer doesn’t win.’

Working to Overcome Resistance, Relapse and Metastasis by Targeting Adaptive Stress and Immunosuppression

We believe that adaptive stress pathways and immunosuppressive tumor microenvironments are key mechanisms by which tumors achieve resistance to treatment and ultimately result in relapse and metastasis.

Despite the clinical improvements that have been made with the use of targeted therapies, cancer cells leverage adaptive stress and immunosuppressive pathways to adapt, survive, and become resistant to treatment.

We are leading the way in the development of innovative cancer therapy candidates that target adaptive stress responses and modulate innate and adaptive immunity.

Our Approach to Novel Targeted and Immunological Therapy Candidate Development

HC-5404 & HC-7366

HC-5404 and HC-7366 are differentiated adaptive stress therapy candidates designed to inhibit PKR-like Endoplasmic Reticulum Kinase (PERK) and modulate General Control Nonderepressible 2 (GCN2), respectively — two kinases that are critical to the Unfolded Protein Response (UPR) and the Integrated Stress Response (ISR) pathways.

Modulating adaptive stress has the potential to target and directly eliminate treatment resistant cells and resolve the stress that limits an anti-cancer immune response.

Odetiglucan

Odetiglucan is a differentiated, systemically administered therapeutic candidate that has been observed to modulate both the innate and adaptive immune system.

It has been shown to bind to a unique combination of receptors on innate immune cells, reprogramming the tumor microenvironment to drive a strong anti-cancer immune response.

Our QuAD³ Platform

Our proprietary QuAD³ (Quantum Artificial Intelligence Drug Discovery and Development) Platform leverages advanced AI and ML strategies to drive robust insights from analysis of complex genomic and multi-omic datasets. QuAD³ is designed to deconvolute the complexity of adaptive stress, which we believe will uncover new actionable insights into cancer biology and help us identify those patients most likely to respond to our therapeutic candidates.

See our recent qML publication.

Visionaries in Oncology

Our team is led by bold thought leaders who believe that transformational discoveries are possible when you integrate and power rigorous, traditional drug discovery methods with computational excellence. We are always seeking like-minded innovators who think beyond the box to join our vision of imagining ‘a world in which cancer doesn’t win.’